Scholar IQ
Try ScholarIQ free
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Cancer Research and Treatments

TopicLeading institutions, researchers & key papers

Cancer Research and Treatments is a topic indexed in ScholarIQ from OpenAlex.

What is known about Cancer Research and Treatments?

ScholarIQrecord summary

This cluster of papers focuses on the use of engineered bacteria, particularly Salmonella typhimurium, for targeted cancer therapy. The research involves various strategies such as tumor-specific colonization, gene delivery, immunotherapy, and metabolic manipulation to induce tumor regression and enhance anti-tumor immunity. Fluorescent protein imaging is utilized to visualize tumor growth, metastasis, and angiogenesis in live animals. Additionally, the cluster explores the use of bacterial vectors for gene therapy and the potential of arginine deprivation as a targeted therapy for certain cancers.

How many works does Cancer Research and Treatments have?

ScholarIQindexed works

Cancer Research and Treatments has 194 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

What is the OpenAlex record for Cancer Research and Treatments?

ScholarIQopenalex

The OpenAlex for Cancer Research and Treatments is on the source record.

What are the most-cited papers on Cancer Research and Treatments?

ScholarIQmost cited works
Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses
Nicholas J. Roberts, Linping Zhang, Filip Jankú, Amanda Collins, Ren-Yuan Bai, Verena Staedtke, Anthony Rusk, David Tung, Maria Miller, Jeffrey J. Roix, Kristen V. Khanna, Ravi Murthy, Robert S. Benjamin, Thorunn Helgason, Ariel D. Szvalb, Justin E. Bird, Sinchita Roy‐Chowdhuri, Halle H. Zhang, Yuan Qiao, Baktiar Karim, Jennifer S. McDaniel, Amanda Elpiner, Alexandra Sahora, Joshua L. Lachowicz, Brenda Phillips, Avenelle I. Turner, Mary K. Klein, Gerald Post, Luis A. Díaz, Gregory J. Riggins, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Chetan Bettegowda, David L. Huso, Mary Varterasian, Saurabh Saha, Shibin Zhou
Science Translational Medicine. 2014397 CitationsOPEN ACCESS
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Yaohui Gao, Dexi Bi, Ruting Xie, Man Li, Jing Guo, Hu Liu, Xianling Guo, Juemin Fang, Tingting Ding, Huiyuan Zhu, Yuan Cao, Meichun Xing, Jiayi Zheng, Qing Xu, Qian Xu, Qing Wei, Huanlong Qin
Signal Transduction and Targeted Therapy. 2021292 CitationsOPEN ACCESS
An Overview of Cancer Treatment Modalities
Zaigham Abbas, Sakina Rehman
InTech eBooks. 2018257 CitationsOPEN ACCESS
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens
James G. Fox, Yan Feng, Elizabeth J. Theve, Arkadiusz R. Raczynski, J Fiala, A. L. Doernte, Matthew L. Williams, José L. McFaline‐Figueroa, John M. Essigmann, David B. Schauer, Steven R. Tannenbaum, Peter C. Dedon, Steven A. Weinman, Stanley M. Lemon, Rebecca C. Fry, A. B. Rogers
Gut. 2009236 CitationsOPEN ACCESS
An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis
Hue H. Luu, Quan Kang, Jong Kyung Park, Weike Si, Qing Luo, Wei Jiang, Hong Yin, Anthony Montag, Michael A. Simon, Terrance D. Peabody, Rex C. Haydon, Carrie Rinker‐Schaeffer, Tong‐Chuan He
Clinical & Experimental Metastasis. 2005231 Citations

Where is Cancer Research and Treatments research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock

How much of the research on Cancer Research and Treatments is open access?

ScholarIQopen access share
60%OPEN ACCESS
Gold
20%
Green
13%
Hybrid
13%
Bronze
13%
Closed
40%

Related on ScholarIQ

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Paper
Pembrolizumab for Early Triple-Negative Breast Cancer
Paper
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Paper
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Paper
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Paper
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Paper
470M+ articles · 14-day free trial